Simon TA, Suissa S, Skovron ML, Frisell T, Askling J, Michaud K, Pedro S, Strangfeld A, Meissner Y, Boers M, Hoffman V, Dominique A, Gomez A, Hochberg MC. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study. Semin Arthritis Rheum. 2024 Feb;64:152313. doi: 10.1016/j.semarthrit.2023.152313
Henk HJ, Kaye JA, Rothman KJ, Becker LK, Legg JC, Li X. Variation by age in neutropenic complications among patients with cancer receiving chemotherapy. Community Oncol. 2013 Jan 1;10(1):16-26.
Thyagarajan (Hoffman) V, Norman H, Alexander KA, Napalkov P, Enger C. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients. Semin Arthritis Rheum. 2012 Dec;42(3):223-33. doi: 10.1016/j.semarthrit.2012.05.004
Oglesby A, Sherif B, Odom D, Leahy M, Qian Y. Time and costs associated with preparing and administering zoledronic acid in patients with breast or prostate cancer and metastatic bone disease. Community Oncol. 2009 Nov 1;6(11):494-502.
Buchanan A, Sugg Skinner C, Calingaert B, Schildkraut J, King R, Marcom K. Cancer genetic counseling in rural North Carolina oncology clinics: program establishment and patient characteristics. Community Oncol. 2009;6(2):70-7.